Suppr超能文献

血红素和血红蛋白的定量分析用于检测血管内溶血。

Quantitative analysis of heme and hemoglobin for the detection of intravascular hemolysis.

机构信息

Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, D-53121, Bonn, Germany; Department of Chemistry, Institute for Integrated Natural Sciences, University of Koblenz, D-56070, Koblenz, Germany.

Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, D-53121, Bonn, Germany.

出版信息

Anal Chim Acta. 2024 Jul 11;1312:342766. doi: 10.1016/j.aca.2024.342766. Epub 2024 May 21.

Abstract

BACKGROUND

Intravascular hemolysis is associated with massive release of hemoglobin and consequently labile heme into the blood, resulting in prothrombotic and proinflammatory events in patients. Though heme is well-known to participate in these adverse effects, it is not monitored. Instead, haptoglobin and hemoglobin serve as clinical biomarkers. The quantification of labile heme together with hemoglobin, however, should be considered in clinical diagnosis as well, to obtain a complete picture of the hemolytic state in patients. So far, quantification techniques for labile heme were not yet systematically analyzed and compared for their clinical application potential, especially in the presence of hemoglobin.

RESULTS

Two commercial assays (Heme Assay Kit®, Hemin Assay Kit®) and five common approaches (pyridine hemochromogen assay, apo-horseradish peroxidase-based assay, UV/Vis spectroscopy, HPLC, mass spectrometry) were analyzed concerning their linearity, accuracy, and precision, as well as their ability to distinguish between hemoglobin-bound heme and labile heme. Further, techniques for the quantification of hemoglobin (Harboe method, SLS method, Hemastix®) were included to study their selectivity for hemoglobin and potential interference by the presence of labile heme. Both, indirect and direct approaches were suitable for the determination of a wide concentration of heme (∼0.02-45 μM) and hemoglobin (∼0.002-17 μM). A clear distinction between hemoglobin-bound heme and labile heme with one method was not possible. Thus, a novel combined approach is presented and applied to human and porcine plasma samples for the determination of hemoglobin and labile heme.

SIGNIFICANCE

Our results demonstrate the need to develop improved techniques to differentiate labile and protein-bound heme for early detection of intravascular hemolysis. Here, we present a novel strategy by combining two spectroscopic methods, which is most reliable as an easy-to-use tool for the determination of hemoglobin and heme levels in plasma samples for the diagnosis of intravascular hemolysis and in basic biomedical research.

摘要

背景

血管内溶血会导致大量血红蛋白和不稳定血红素释放到血液中,从而导致患者发生血栓形成和炎症反应。尽管血红素已知参与这些不良反应,但并未进行监测。相反,触珠蛋白和血红蛋白作为临床生物标志物。然而,在临床诊断中,应同时考虑到不稳定血红素和血红蛋白的定量,以全面了解患者的溶血状态。到目前为止,尚未对不稳定血红素的定量技术进行系统分析和比较,以评估其在临床应用中的潜力,尤其是在存在血红蛋白的情况下。

结果

我们分析了两种商业检测试剂盒(血红素检测试剂盒、血红素检测试剂盒)和五种常见方法(吡啶血红素比色法、脱辅基辣根过氧化物酶法、紫外/可见光谱法、高效液相色谱法、质谱法)的线性、准确性和精密度,以及它们区分血红蛋白结合血红素和不稳定血红素的能力。此外,还包括血红蛋白定量技术(Harboe 法、SLS 法、Hemastix®),以研究它们对血红蛋白的选择性以及不稳定血红素存在时的潜在干扰。间接和直接方法都适用于广泛浓度范围的血红素(约 0.02-45 μM)和血红蛋白(约 0.002-17 μM)的测定。一种方法无法明确区分血红蛋白结合血红素和不稳定血红素。因此,我们提出并应用了一种新的组合方法来测定人血浆和猪血浆中的血红蛋白和不稳定血红素。

意义

我们的研究结果表明,需要开发改进的技术来区分不稳定血红素和蛋白结合血红素,以便早期发现血管内溶血。在此,我们提出了一种新的策略,即结合两种光谱方法,作为一种简单易用的工具,用于测定血浆样品中的血红蛋白和血红素水平,以诊断血管内溶血和基础生物医学研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b49/11625178/16a14293a737/nihms-2037623-f0002.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验